Medeva Hepagene
Executive Summary
FDA issues a refuse-to-file letter for the trivalent recombinant hepatitis B vaccine BLA submitted Feb. 10. The letter, issued the week of April 5, questions whether the number of subjects in the clinical database of the application is enough, Medeva said. FDA has also requested modifications to and further information on good manufacturing practices for the vaccine and information on equipment, processes and systems validation protocols as well as comparative clinical data from final manufacturing lots. Medeva plans to meet with FDA in May to address the issues
You may also be interested in...
Celltech Medeva Hepacare Hep B Vaccine Targeted For End-2000 U.K. Launch
Celltech Medeva's three-antigen hepatitis B vaccine Hepacare is slated for a late-2000 U.K. launch following a March 16 recommendation by EMEA's Committee for Proprietary Medicinal Products.
Celltech Medeva Hepacare Hep B Vaccine Targeted For End-2000 U.K. Launch
Celltech Medeva's three-antigen hepatitis B vaccine Hepacare is slated for a late-2000 U.K. launch following a March 16 recommendation by EMEA's Committee for Proprietary Medicinal Products.
Celltech Chiroscience Acquisition Of Medeva Provides Marketing Muscle
Medeva will bring a sales force of 400 reps, including 180 reps in the U.S., to the proposed merger with Celltech Chiroscience.